QB3 Webinar: Vasant Jadhav, Alnylam. "Delivering on the Promise of RNAi Therapeutics"

Alnylam, based in Cambridge, MA, has led the translation of RNAi from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, their first medicine, ONPATTRO (patisiran), became the world’s first approved RNAi therapeutic. Their second medicine, GIVLAARI (givosiran), was approved in 2019, followed closely by OXLUMO (lumasiran), cleared in 2020. They are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and CNS and ocular diseases. Watch the video to learn how Alnylam conceives and develops therapies in this exciting new area.

[@olgagreb7554]

Killer video 👐! Get the results you deserve - P-R-O-M-O-S-M !!!